Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Total Neoadjuvant Treatment
The First People's Hospital of Lianyungang
Biliary Tract Neoplasms
1 trial -
Treatment as Usual
Camp4 Therapeutics Corp
Post-Traumatic Stress Disorder
1 trial -
UC-BCG-2312
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
UC-GIG-2308
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
UC-GIG-2311
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
VLY-686
Vanda Pharmaceuticals Netherlands B.V.
Treatment-resistant Pruritus Associated With Atopic Dermatitis
1 trial -
Vancomycin Pre-Treatment
Seres Therapeutics
Ulcerative Colitis
1 trial -
Zelboraf 240 mg film-coated tablets
Ningbo Cancer Hospital
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
1 trial -
conventional therapy plus low dose hUC-MSCs treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
idecabtagene vicleucel
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)
1 trial -
rituximab /Dexamethasone/cyclophosphamide
The First People's Hospital of Lianyungang
Treatment
1 trial -
01-DAP-BIO-24
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.
1 trial -
01API2024
Lacuna Pharma Pty Ltd
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
1 trial -
01INDA2024
Lacuna Pharma Pty Ltd
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
1 trial -
02API2024
Lacuna Pharma Pty Ltd
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
1 trial -
22534
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
3137001
Orion Laboratories Pty.
short-term treatment of insomnia
1 trial -
400314
HALEON AUSTRALIA PTY LTD
For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries
1 trial -
610
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
1 trial -
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Enliven Therapeutics
Chronic myeloid leukemia
1 trial -
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer
Amgen
Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
1 trial -
A trial to learn how baxdrostat affects the heartbeat in healthy participants
AstraZeneca AB
Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension
1 trial -
ADO-01-24
Lacuna Pharma Pty Ltd
Patients suffering from cancer without further treatment options.
1 trial -
AG120-C-001
The George Institute
AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.